Patents by Inventor Felix Cleenmann

Felix Cleenmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240173385
    Abstract: The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.
    Type: Application
    Filed: October 27, 2023
    Publication date: May 30, 2024
    Inventors: Kennett Sprogøe, Lars Holten-Andersen, David Brian Karpf, Felix Cleenmann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
  • Patent number: 11224661
    Abstract: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: January 18, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprogøe, Harald Rau, Ana Bernhard, Ulrich Hersel, Felix Cleenmann, Thomas Wegge
  • Publication number: 20190022237
    Abstract: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
    Type: Application
    Filed: January 5, 2017
    Publication date: January 24, 2019
    Inventors: Kennett SPROGØE, Harald Rau, Ana Bernhard, Ulrich Hersel, Felix Cleenmann, Thomas Wegge